Results 31 to 40 of about 15,585 (162)

Clinical implication of ticagrelor monotherapy in patients with small vessel coronary artery disease: results from the TICO randomized trial

Frontiers in Cardiovascular Medicine, 2023
BackgroundThe aim of this study was to evaluate the efficacy and safety of ticagrelor monotherapy in patients with small vessel disease compared with ticagrelor-based DAPT within the Ticagrelor Monotherapy after 3 Months in the Patients Treated with New ...
Jae Young Cho, Donghyeon Joo, Kyeong Ho Yun, Byeong-Keuk Kim, Myeong-Ki Hong, Yangsoo Jang, Seok Kyu Oh   +6 more
doaj   +1 more source

Mechanical Thrombus Aspiration for a Young STEMI Patient With Plaque Erosion: Time for a Stent‐Free Approach?

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT A 34‐year‐old man with no cardiovascular history presented with anterior ST‐elevation myocardial infarction and a large thrombotic occlusion of the mid left anterior descending artery. Following potent antithrombotic therapy and mechanical thrombus aspiration, angiography revealed vessel patency without residual significant stenosis, allowing ...
Domenico Simone Castiello, Francesco Greco, Antonio Curcio, Alberto Polimeni   +3 more
wiley   +1 more source

Does the level of myocardial injury differ in primary angioplasty patients loaded first with clopidogrel and the ones with ticagrelor?

Anatolian Journal of Cardiology, 2020
Objective: In daily clinical practice, we encounter ST segment elevation myocardial infarction (STEMI) patients loaded with clopidogrel upon admission to primary angioplasty.
Nil Ozyuncu, Hüseyin Göksülük, Turkan Seda Tan, Kerim Esenboga, Yusuf Atmaca, Çetin Erol   +5 more
doaj   +1 more source

Coronary Perforation During Excimer Laser Angioplasty in a Patient With Prior Thoracic Radiotherapy

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Management of heavily calcified coronary lesions remains challenging despite advances in plaque‐modifying technologies. Excimer laser coronary angioplasty (ELCA) is an effective adjunctive strategy with a low risk of no‐reflow. Case Summary A 75‐year‐old woman with non–ST‐segment elevation acute coronary syndrome and severe left ...
Francesco Maria Sparasci, Alessandro Cafaro, Dionigi Fischetti, Alessandro Mandurino‐Mirizzi   +3 more
wiley   +1 more source

Interaction of Operator−Patient Sex on Peri‐Procedural Treatments and Major Coronary Outcomes After Percutaneous Coronary Intervention

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background There are limited data evaluating the association between operator−patient sex, and outcomes in patients undergoing percutaneous coronary intervention (PCI). Methods We included 138,112 consecutive PCI procedures in patients presenting with acute coronary syndrome (ACS) in England and Wales, 2017−2020.
Sharon A. Ayayo, Vicky P. Taxiarchi, Angela Jerath, Evangelos Kontopantelis, Sonya N. Burgess, Sarah Zaman, Mamas A. Mamas   +6 more
wiley   +1 more source

Pleiotropic Effects of Ticagrelor: Influence on CYP4F2 Gene and Protein Expression in HUVEC and HepG2, and Escherichia coli Bacterial Survival

Drug Design, Development and Therapy, 2022
Ugne Meskauskaite,1 Silvija Andruskeviciute,1 Ieva Ciapiene,1 Agne Giedraitiene,2 Vaiva Lesauskaite,1 Vacis Tatarunas1 1Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania; 2Institute of Microbiology and Virology ...
Meskauskaite U, Andruskeviciute S, Ciapiene I, Giedraitiene A, Lesauskaite V, Tatarunas V   +5 more
doaj  

CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches

Clinical Pharmacology &Therapeutics, EarlyView.
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles.
Rachael M. Stone, Glenda Hoffecker, April Schultz, Brittney H. Davis, Salma A. Bargal, Amber L. Beitelshees, Nihal El Rouby, Madeline Norris, Kevin J. Rodriguez, Nita Limdi, Larisa H. Cavallari, Craig R. Lee   +11 more
wiley   +1 more source

Progress in the clinical effects and adverse reactions of ticagrelor

Thrombosis Journal
Background Ticagrelor is a novel receptor antagonist that selectively binds to the P2Y12 receptor, thereby inhibiting adenosine diphosphate (ADP)-mediated platelet aggregation.
Peng Wei, Xiaoqing Wang, Qiang Fu, Bangming Cao   +3 more
doaj   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Ticagrelor — a legend of modern cardiology

Российский кардиологический журнал
The article presents the evidence on the basis of which the ticagrelor is used in patients with various forms of coronary artery disease, including both acute and chronic.
S. R. Gilyarevsky
doaj   +1 more source